In this study, we showed that Rspo1 is frequently upregulated in gliomas (43.4%, 102/235), particularly in high-grade glioma (stages III and IV, 52.3%, 68/130), and that a positive association exists between Rspo1 expression and advanced clinicopathological features. This evidence concerns the gene RSPO1 and central nervous system cancer.